Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 6/20 | 0.34 |
| ▸ | HTR2B | P41595 | 6/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17784701 | 0.87 | SLC6A4 (0.36) | MEN1PKMKMT2ASLC6A4HTR2A | |
| SCHEMBL6768684 | 0.82 | CA12 (0.44) | HTR2ADRD2 | |
| SCHEMBL17784694 | 0.81 | MAPT (0.35) | SLC6A4HTR2AKCNH2DRD2 | |
| SCHEMBL1178457 | 0.81 | DRD2 (0.38) | SLC6A4HTR2AKCNH2SLC6A2DRD2 | |
| SCHEMBL18805728 | 0.81 | ATM (0.40) | MEN1KMT2ADRD2PTGER1NPSR1 | |
| SCHEMBL2989844 | 0.80 | S1PR4 (0.42) | SLC6A2SLC6A3 | |
| SCHEMBL16535794 | 0.79 | IDO1 (0.45) | HTR2ADRD2 | |
| SCHEMBL12378188 | 0.78 | CYP1A2 (0.43) | SLC6A4HTR2ASLC6A2HTR2CHTR2B | |
| SCHEMBL4978091 | 0.77 | SLC6A4 (0.39) | MEN1PKMKMT2ASLC6A4KCNH2 | |
| SCHEMBL1094866 | 0.77 | S1PR4 (0.34) | MEN1PKMKMT2ADRD2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183234-B2 | Tricyclic guanidine derivatives as sodium-proton exchange inhibitors | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-7834001-B2 | N-(10,10-Dioxo-10,11-dihydro-5-oxa-10-lambda*6*-thia-dibenzo[a.d]cycloheptene-8-carbonyl)-guanidine; tumor necrosis factor inhibitors; sodium-proton exchange inhibitors for treatment of organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-11-16 | — | — | US | disclosed |
| US-20100267690-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-21 | — | — | US | disclosed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20070299051-A1 | Tricyclic Guanidine Derivatives as Sodium-Proton Exchange Inhibitors | NICHOLAS PIRAMAL INDIA LIMITED. (IN) | 2007-12-27 | — | — | US | disclosed |
| WO-2007136714-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| EP-1812420-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | Nicholas Piramal India Limited (IN) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006051476-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267690-A1 | TRICYCLIC GUANIDINE DERIVATIVES AS SODIUM-PROTON EXCHANGE INHIBITORS | ATP2A1, ATP2A3, KCNN4 | MEN1 4261/4885PKM 1915/4885KMT2A 3477/4885 |
| US-20070299051-A1 | Tricyclic Guanidine Derivatives as Sodium-Proton Exchange Inhibitors | ATP2A1, ATP2A3, KCNN4 | MEN1 4261/4885PKM 1915/4885KMT2A 3477/4885 |
| US-20080058315-A1 | Integrase inhibitors | TYMP, DNTT, PAICS | MEN1 4674/4885PKM 3333/4885KMT2A 1657/4885 |
| US-20090306054-A1 | INTEGRASE INHIBITORS | TYMP, POLR2E, CCNI | MEN1 4614/4885PKM 2762/4885KMT2A 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.